Graziani G, Chiarini C, Limido D, Cantaluppi A, Marai P, Pincella G, Piaia F, Zucchelli P, Locatelli F, Ponticelli C
Urology. 1987 Sep;30(3):293-7. doi: 10.1016/0090-4295(87)90262-7.
Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4). The posology is one capsule (T 250 mg + S 200 mg) daily, after a loading dose of two capsules on the first day. To evaluate the clinical value of Kelfiprim (KP) vs co-trimoxazole (CO) in urinary tract infection (UTI) a controlled multicenter double-blind trial (MDBT) was carried out in 76 patients suffering from persistent and recurrent UTIs. About 90 per cent response rate (sterile urine at the end of treatment) was obtained for KP and about 85 per cent for CO in recurrent UTI. In persistent UTI the rate of recovery was 66.8 per cent and 53 per cent for KP and CO, respectively. Safety of treatments was excellent in 97 per cent of patients treated with Kelfiprim and 87 per cent treated with co-trimoxazole. Two patients, one in each group, were dropped from the study because of adverse reactions.
凯尔氟普明（KP）是一种新型杀菌剂，含有甲氧苄啶（T）和长效磺胺磺胺甲吡嗪（S）（比例为5:4）。用药剂量为首日服用两粒胶囊作为负荷剂量，之后每日服用一粒胶囊（T 250毫克+S 200毫克）。为评估凯尔氟普明（KP）与复方新诺明（CO）治疗尿路感染（UTI）的临床价值，对76例患有持续性和复发性UTI的患者进行了一项对照多中心双盲试验（MDBT）。在复发性UTI中，KP的有效率约为90%（治疗结束时尿液无菌），CO约为85%。在持续性UTI中，KP和CO的治愈率分别为66.8%和53%。接受凯尔氟普明治疗的患者中97%以及接受复方新诺明治疗的患者中87%的治疗安全性良好。每组各有一名患者因不良反应退出研究。
